Due to the important role of IL-6 in mediating inflammation, IL-6 inhibitors (IL6i) have been developed and, currently, there are two licensed for the treatment of RA; tocilizumab (TCZ) and sarilumab [11, 12]. The gene discussed is IL6; the disease is rheumatoid arthritis.